Printer Friendly

FDA CLEARS AGOURON PHARMACEUTICALS TO COMMENCE SECOND CLINICAL STUDY OF PSORIASIS DRUG

 SAN DIEGO, Jan. 12 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) announced that it has been authorized by the U.S. Food and Drug Administration to begin a second clinical study of its topical anti-psoriatic drug designated AG-85. The new clinical study of AG-85 will begin immediately and will involve up to 24 psoriasis patients. The study will be conducted concurrently by Dr. Nicholas Lowe at the Skin Research Foundation of California in Santa Monica and by Dr. Gerald D. Weinstein at the University of California, Irvine.
 AG-85 was designed by Agouron scientists to halt the abnormal proliferation of psoriatic skin cells by inactivating a key enzyme known as thymidylate synthase. An initial pilot clinical study of 0.1 percent AG-85 solution applied topically to 10 psoriasis patients was completed in April 1992. The new clinical study will evaluate a 1.25 percent topical cream formulation of AG-85 and will require approximately six months to complete.
 Agouron Pharmaceuticals Inc. is a pioneer and leader of a technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 -0- 1/12/93
 /CONTACT: Peter Johnson, president and CEO, or Donna Nichols, director of corporate communications, of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH)


CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU:

JB-EH -- SD001 -- 3857 01/12/93 09:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:250
Previous Article:CRAYOLA CELEBRATES 90 YEARS OF COLORWITH BIGGEST 'DRAW' IN CRAYON HISTORY
Next Article:FLUKE REPORTS OPERATING RESULTS FOR FIRST QUARTER 1993
Topics:


Related Articles
AGOURON PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG
AGOURON PHARMACEUTICALS BEGINS CLINICAL TESTING OF PSORIASIS DRUG
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
AGOURON SUSPENDS DEVELOPMENT OF PSORIASIS AGENT
AGOURON PHARMACEUTICALS EXPANDS CLINICAL TESTING OF SECOND CANCER DRUG INTO UNITED STATES
AGOURON PHARMACEUTICALS EXTENDS CLINICAL TESTING OF HIV DRUG INTO U.S.
Agouron Pharmaceuticals Receives Clearance To Commence Clinical Trials Of New Cancer Drug
Agouron To Submit NDA For Anti-HIV Drug VIRACEPT(TM)
Agouron To Submit NDA For Anti-HIV Drug VIRACEPT(TM)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters